Slowsurg Company
Slowsurg was founded in 2025 after several years of research and development performed first at the University of Brussels (Université Libre de Bruxelles, ULB) in collaboration with Erasme Hospital and the Brussels Medical Device Center (BMDC). The company benefits from all the data carried out by the teams of these
entities.
Clinical trials are performed in close collaboration with Erasme hospital (A world of care dedicated to our patients | Hôpital Erasme). The company is supported by private investors, the Cremer foundation (Endoscopie thérapeutique), Impactheo (company managing the shares of ULB in spinoff companies), Sambrinvest (Sambrinvest soutient tous vos projets – Sambrinvest) and Finance & Invest Brussels.
Our partners:
Slowsurg is performing new research & developments to apply the MAGUSTM concept to other indications. We have current project aiming to develop an innovative instrument for remodeling the digestive tract, specifically for creating large anastomoses. Based on the MAGUSTM concept, the treatment relies on slow cutting induced by controlled pressure, causing progressive ischemia leading to necrosis, followed by healing. Slowsurg is supported by Wallonn region and other institutions in these R&D activities.
